Go To Global Site

Welcome to UCB Australia

UCB history in Australia

1981

UCB Australia was incorporated as a company on 31st March

2001

Keppra^® (levetiracetam), is registered for use in Australia for epilepsy

2007

Neupro^® (rotigotine) is registered for use in Australia for Parkinson’s disease

2009

Vimpat^® (lacosamide) is registered for use in Australia in epilepsy.

2010

Cimzia^®(certolizumab pegol) is registered for use in Australia for Rheumatoid Arthritis

2015

UCB is delivering on its growth promise with double digit growth of revenues and profitability. With major pipeline milestones reached in 2015, the company is paving the way for the future with promising assets meant to further create value for patients